The same molecule that made COVID-19 vaccines possible can do two very different jobs in medicine. In cancer immunotherapy, mRNA teaches the immune system to recognize and attack tumor cells. In protein replacement therapy, it instructs a patient's own cells to manufacture a protein their body lacks. The molecule is identical in principle; what changes is the protein it encodes and the biological problem that protein is designed to solve.

Introduction: mRNA Beyond Vaccines

When mRNA became a household word during the pandemic, many assumed the technology had appeared overnight. In fact, as the Oligonucleotide Therapeutics Society notes, it had been in development for two decades, with uses ranging from infectious disease vaccines and cancer immunotherapy to protein replacement therapy, gene therapy, and cell reprogramming.

The core idea is simple. Messenger RNA is a set of temporary instructions. Delivered into the body, it tells cells to produce a specific protein. That protein could be a viral fragment that trains immunity, a tumor antigen that marks cancer for destruction, or a functional enzyme a patient's genes cannot make. As a review in Cureus puts it, research into mRNA for therapeutic purposes beyond infectious diseases may revolutionize treatment for genetic and chronic conditions, introducing a new direction for medicine.

mRNA in Cancer Immunotherapy

Why does the immune system fail against cancer? Because tumor cells arise from the body's own tissue, immune defenses often do not recognize them as threats. Therapeutic cancer vaccines are built to overcome exactly this recognition failure.

Here, mRNA is designed to encode tumor-specific antigens. Once cells produce those antigens, they serve to educate the immune system, teaching it what cancer looks like. The trained defenses can then target and eliminate cancerous cells. Unlike preventive vaccines, therapeutic cancer vaccines help the immune system identify and attack cancer cells that already exist, and some can be personalized to the specific mutations in a patient's tumor, as Atlantic Health Partners explains.

This is no longer purely theoretical. In August 2026, Moderna and Merck announced positive results from a Phase 3 clinical trial involving more than 1,000 patients with melanoma. The Oligonucleotide Therapeutics Society also reports that companies such as Kernal Biologics are developing mRNA-based immunotherapies for cancer using platforms that decrease immunogenicity and enable cell-specific protein expression, while CureVac is pursuing cancer immunotherapy alongside vaccines and protein replacement programs.